Brain Tumor Clinical and Clinical Research Program

脑肿瘤临床和临床研究计划

基本信息

  • 批准号:
    7733491
  • 负责人:
  • 金额:
    $ 205.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

The NOB has made substantial progress towards building an infrastructure necessary for fulfilling its mission of developing new and improved therapies for children and adults with brain and spinal cord tumors. Below are partial lists of accomplishments in the building of the Brain Tumor Clinical and Clinical Research Program: Established an NIH-wide multidisciplinary Brain Tumor Clinic with active participation from three different NCI Branches (ROB, MOCRU, CCRLP), five different NIH Institutions (NCI, NINDS, NEI, NHLBI, NIMH), and five different Clinical Center Programs (Neuroradiology, Psychiatry, Pain and Palliation, Rehabilitation Medicine, Social Work). Expertise represented in the clinic includes Medical Oncology, Pediatric Oncology, Radiation Oncology, Neurosurgery, Neurology, Ophthalmology, Cardiology, Psychiatry, Endocrinology, Social Work, and Rehabilitation Medicine; Assembled a primary neuro-oncology clinical care/research team, which now consists of 4 neuro-oncologists, 6 NOB-trained neuro-oncology nurse practitioners, 3 research nurses, 1 neuro-oncology fellow, 2 patient coordinators, 1 study coordinator, and 5 data managers; Established a robust neuro-oncology consultation service, in which local/regional patients are seen and followed at the NIH (all patients are accrued to a CNS tumor natural history protocol; distant patients may just have radiology/medical records reviewed; Serving as Chair of the Search Committee, Howard Fine helped recruit two new tenure track clinician/scientist brain tumor neurosurgeons to NINDS/NCI leading to a total of 5 clinically active brain tumor neurosurgeons in the Surgical Neurology Branch, NINDS; Activated more than 30 IRB approved clinical trials with an additional 4 expected to be approved by fall 2005, for a total of 30 protocolscompared to just 1 protocol existing for primary brain tumors at the NIH when the NOB was formed in 2000 (a prior radiation protocol that had accrued less than 10 patients in total). The 30 new protocols comprise: Accrue more than 200 primary brain tumor patients to NOB IRB-approved clinical trials per year; Saw more than 500 new primary brain tumor patients (almost all gliomas) and between 2000-3000 follow-up patients over the last 12 months, up from less than 10 patients with malignant brain tumor seen at NIH in the year before the NOB was formed (1999). Additionally, the NOB reviews 2-6 new mail-in patient consults per week. Provides almost all neuro-oncology services for Walter Reed Medical Center, the Portsmouth Naval Hospital, and the Naval Medical Center in Bethesda; Is a full official and participating member and provides translational scientific expertise to both CTEP-sponsored brain tumor clinical trial consortia (NABTC, NABTT); Established close collaborative clinical programs with Johns Hopkins Medical Center, George Washington Medical Center, Fairfax Inova and Washington Hospital Center and a wide array of private neurosurgical, radiation, and oncology practice groups locally and nationally; Created one of only a few organized neuro-oncology fellowship training programs in the United Statesa three-institution joint research training program between the NIH, Johns Hopkins Medical Center, and Childrens National Medical Center in Washington, D.C.; Identified five compounds through the preclinical screening program that have since been brought forward to clinical trials at the NIH (CC8490, LY317615, Velcade + Tamoxifen, CC5013, Talampanel). Activated 9 clinical trials as a direct result of translational work performed within the Neuro-Oncology Laboratory.
NOB在建设必要的基础设施方面取得了实质性进展, 履行其使命,为儿童和成人开发新的和改进的治疗方法, 脑和脊髓肿瘤。以下是在建设和平方面取得的部分成就。 脑肿瘤临床和临床研究计划:建立了一个NIH范围的 来自三个不同NCI的多学科脑肿瘤诊所的积极参与 分支机构(ROB,MOCRU,CCRLP),五个不同的NIH机构(NCI,NINDS,NEI,NHLBI,NIMH), 和五个不同的临床中心计划(神经放射学,精神病学,疼痛和姑息, 康复医学、社会工作)。诊所所代表的专业知识包括医疗 肿瘤科、儿科肿瘤科、放射肿瘤科、神经外科、神经内科、眼科, 心脏病学、精神病学、内分泌学、社会工作和康复医学 初级神经肿瘤临床护理/研究团队,目前由4名神经肿瘤学家组成, 6名NOB培训的神经肿瘤学执业护士,3名研究护士,1名神经肿瘤学研究员, 2名患者协调员,1名研究协调员和5名数据管理员;建立了一个强大的 神经肿瘤学咨询服务,在该服务中, NIH(所有患者均符合CNS肿瘤自然史方案;远处患者) 可能只是有放射学/医疗记录审查;担任搜索委员会主席, 霍华德费恩帮助招募了两名新的终身教职临床医生/科学家脑肿瘤神经外科医生 到NINDS/NCI,总共有5名临床活跃的脑肿瘤神经外科医生, NINDS外科神经病学分支;激活了30多项IRB批准的临床试验, 预计到2005年秋季将批准另外4项议定书,总共30项议定书, 当NOB于2000年成立时,NIH存在1项针对原发性脑肿瘤的方案(a 先前的放射方案总共累积了少于10名患者)。30个新协议 包括:将200多名原发性脑肿瘤患者纳入NOB IRB批准的临床 每年有超过500例新的原发性脑肿瘤患者(几乎所有的胶质瘤), 在过去12个月内,2000-3000名随访患者,从不到10名患者增加到 在NOB成立前一年(1999年),NIH发现了恶性脑肿瘤。 此外,NOB每周审查2-6例新的邮寄患者咨询。提供几乎所有 沃尔特里德医疗中心,朴茨茅斯海军医院和 位于贝塞斯达的海军医疗中心;是正式成员和参与成员, 向CTEP赞助的脑肿瘤临床试验联盟提供转化科学专业知识 (NABTC,NABTT);与约翰霍普金斯医学中心建立密切合作的临床项目 中心,乔治华盛顿医疗中心,费尔法克斯Inova和华盛顿医院中心和一个 广泛的私人神经外科,放射和肿瘤学实践团体, 在全国范围内;创建了为数不多的有组织的神经肿瘤学奖学金培训计划之一, 美国国家卫生研究院、约翰 华盛顿,华盛顿特区的霍普金斯医疗中心和儿童国家医疗中心;识别 五种化合物通过临床前筛选计划, NIH的临床试验(CC 8490、LY 317615、万珂+他莫昔芬、CC 5013、Talampanel)。 作为在本组织内进行的翻译工作的直接结果,启动了9项临床试验。 神经肿瘤学实验室。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Howard Fine其他文献

Howard Fine的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Howard Fine', 18)}}的其他基金

Canine Glioma and Embryonic Neural Stem Cell Project
犬神经胶质瘤和胚胎神经干细胞项目
  • 批准号:
    8552977
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
Brain Tumor Clinical and Clinical Research Program
脑肿瘤临床和临床研究计划
  • 批准号:
    8554177
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
The Pre-clinical and Clinical Development of Novel Molecularly Target
新型分子靶点的临床前和临床开发
  • 批准号:
    7592987
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
探索干细胞生物学在神经胶质瘤中的治疗潜力
  • 批准号:
    7965746
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
SCF as a Novel CNS and Glioma-Derived Angiogenic Factor and SC Chemotaxic Factor
SCF 作为一种新型 CNS 和神经胶质瘤衍生的血管生成因子和 SC 趋化因子
  • 批准号:
    7966056
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
The Role of miRNAs in Glioma Stem Cell and Glioma Biology
miRNA 在神经胶质瘤干细胞和神经胶质瘤生物学中的作用
  • 批准号:
    7966059
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
探索干细胞生物学在神经胶质瘤中的治疗潜力
  • 批准号:
    8157495
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
The Role of miRNAs in Glioma Stem Cell and Glioma Biology
miRNA 在神经胶质瘤干细胞和神经胶质瘤生物学中的作用
  • 批准号:
    8349327
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
Elucidation and Exploitation of GSK3 as a Novel Glioma Therapeutic Target
GSK3 作为新型神经胶质瘤治疗靶点的阐明和开发
  • 批准号:
    8552857
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:
Brain Tumor Animal Therapeutics Core
脑肿瘤动物治疗核心
  • 批准号:
    8763760
  • 财政年份:
  • 资助金额:
    $ 205.16万
  • 项目类别:

相似海外基金

Pioneering reproductive biotechnology innovations for equine breeding
开创马匹育种生殖生物技术创新
  • 批准号:
    LP230100156
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Linkage Projects
Industrial Biotechnology Innovation Cluster
产业生物技术创新集群
  • 批准号:
    EP/Y024168/1
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Research Grant
Environmental Biotechnology Innovation Centre
环境生物技术创新中心
  • 批准号:
    BB/Y008332/1
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Research Grant
Shear Innovation: Valorising wool waste using biotechnology to enhance horticultural peat-free growing media
剪切创新:利用生物技术提高羊毛废料的价值,以增强园艺无泥炭生长介质
  • 批准号:
    10106787
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Launchpad
Conference: Translating Molecular Science Innovations into Biotechnology Solutions
会议:将分子科学创新转化为生物技术解决方案
  • 批准号:
    2419731
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Standard Grant
MFB: Partnerships to Transform Emerging Industries - RNA Tools/Biotechnology: Stabilizing Hairpin Inserts in RNA Virus Induced Gene Silencing Vectors
MFB:合作变革新兴产业 - RNA 工具/生物技术:稳定 RNA 病毒诱导基因沉默载体中的发夹插入
  • 批准号:
    2330663
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Standard Grant
I-Corps: Translation potential of a miniaturized biotechnology platform for nucleic acid extraction, purification, and library preparation
I-Corps:用于核酸提取、纯化和文库制备的小型生物技术平台的转化潜力
  • 批准号:
    2421022
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Standard Grant
NSF Convergence Accelerator Track M: Biofilm-based Corrosion Control using 3D Printed Biotechnology
NSF 融合加速器轨道 M:使用 3D 打印生物技术进行基于生物膜的腐蚀控制
  • 批准号:
    2344389
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Standard Grant
Engineering Biology Hub for environmental processing and recovery of metals; from contaminated land to industrial biotechnology in a circular economy
用于环境处理和金属回收的工程生物中心;
  • 批准号:
    BB/Y008456/1
  • 财政年份:
    2024
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Research Grant
Conference: 2023 Chloroplast Biotechnology GRC & GRS: Harnessing the SynBio Revolution for Metabolic Engineering and Enhanced Photosynthesis
会议:2023年叶绿体生物技术GRC
  • 批准号:
    2243932
  • 财政年份:
    2023
  • 资助金额:
    $ 205.16万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了